| 摘要: |
| 目的分析乳腺癌患者行新辅助化疗前后其肿瘤组织雌激素受体（ER）、孕激素受体（PR）、人类表皮生长因子受体2（Her-2）及细胞增殖抗原（Ki-67）的表达情况，探讨这些指标的变化及其临床意义。方法选择2010年1月至2014年8月收治的采用ET方案进行新辅助化疗4个周期并成功实施乳腺癌改良根治术的女性原发性乳腺癌患者82例，对比患者新辅助化疗前空芯针穿刺标本与新辅助化疗后手术标本的ER、PR、Her-2及Ki-67的表达情况（采用免疫组化S-P法检测）。结果化疗后有38例（80.85%）Ki-67表达发生改变，其中阴性转为阳性0例，阳性转为阴性20例，化疗前后Ki-67表达变化的差异有统计学意义（P＝0.00）；有14例（29.79%）ER表达发生改变，17例（36.17%）PR表达发生改变，9例（23.08%）Her-2表达发生改变，但3项指标化疗前后表达变化的差异均无统计学意义（均P＞0.05）。结论乳腺癌组织Ki-67的变化主要表现为由新辅助化疗前的高表达转变为化疗后的低表达，提示高表达Ki-67的肿瘤细胞对化疗较为敏感，化疗前检测乳腺癌组织Ki-67的表达对预测化疗效果有重要意义。虽然ER、PR、Her-2的改变差异无统计学意义，但仍有部分患者发生了变化，针对这部分患者有必要适当调整治疗计划。 |
| 关键词: 乳腺癌 新辅助化疗 雌激素受体 孕激素受体 人类表皮生长因子受体 2 细胞增殖抗原 |
| DOI： |
| 分类号: |
| 基金项目:衡水市科技局科研基金项目 |
|
| Changes of biological indexes in patients with breast cancer after neoadjuvant chemotherapy |
|
JIA Wei,ZHANG Hongzhen,WNAG Wenjuan,ZHAO Guangyuan,JIANG Yurong,LI Haiping
|
|
Harrison Internation Peace Hospital
|
| Abstract: |
| Objective To assess the expressions of biological indexes in patients with breast cancer after neoadjuvant chemotherapy (NAC). Methods Eighty two patients with primary breast cancer received 4-cycles of NAC with ET regimen from January 2010 to August 2014. The expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2(Her-2) and Ki-67 in needle biopsy specimens before NAC and in surgically resected specimens were detected by immunohistochemical S-P method. The changes of expression of above biological indexes after NAC were analyzed. Results The expression levels of Ki-67 were changed in 80.85% patients, among whom 20 cases were changed from positive to negative (P＝0.00) . The expression of ER was changed in 14 patients (29.79%), the expression of PR was changed in 17 cases(36.17%), the expression of Her-2 was changed in 9 cases (23.08%). Conclusion The expression of Ki-67 changes after NAC, indicating that Ki-67 may be a sensitive index to chemotherapy. The expression of ER, PR and Her-2 changes in some patients after NAC,
suggesting that it is necessary to adjust the treatment regimen for these patients. |
| Key words: Breast cancer Neoadjuvant chemotherapy Estrogen receptor Progesterone receptor Human epider- mal growth factor receptor-2 Nuclear-associated antigen Ki-67 |
